Genprex (NASDAQ:GNPX) Trading Down 2.4% – Should You Sell?

Genprex (NASDAQ:GNPX)’s share price traded down 2.4% during mid-day trading on Tuesday . The company traded as low as $1.99 and last traded at $2.02. 248,165 shares traded hands during trading, a decline of 79% from the average session volume of 1,202,952 shares. The stock had previously closed at $2.07.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Genprex in a research note on Thursday, January 22nd. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock has an average rating of “Sell”.

Genprex Trading Down 2.4%

The business’s 50-day simple moving average is $2.25 and its 200-day simple moving average is $5.42. The company has a market cap of $6.31 million, a PE ratio of -0.08 and a beta of -0.77.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Genprex stock. Susquehanna International Group LLP raised its holdings in Genprex (NASDAQ:GNPX) by 11.7% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 340,056 shares of the company’s stock after acquiring an additional 35,661 shares during the quarter. Susquehanna International Group LLP owned about 27.20% of Genprex worth $58,000 at the end of the most recent quarter. 14.05% of the stock is owned by institutional investors.

Genprex Company Profile

Genprex, Inc is a clinical-stage gene therapy company focused on developing novel, first-in-class treatments for cancer and diabetes. Its proprietary technology employs targeted nanoparticle delivery of therapeutic genes designed to address the underlying genetic drivers of disease. Genprex’s lead oncology candidate, Oncoprex immunogene therapy, is being evaluated for patients with non-small cell lung cancer, with the goal of restoring tumor suppressor function and enhancing response to existing targeted therapies in clinical trials across the United States.

In addition to its oncology pipeline, Genprex is advancing GPTX-203, a gene therapy candidate aimed at improving pancreatic beta-cell function in patients with type 1 diabetes.